Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3
- 10 January 2014
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 86 (4) , 707-712
Abstract
Response to antiviral therapy for hepatitis C virus (HCV) depends upon the genotype and host immune response. IL28b gene mutations have been shown to modulate host antiviral immune response against genotype 1. However, the predictive value of IL28b polymorphism in genotype 3 HCV patients is largely unknown. The association of IL28b polymorphism with virological response was studied in 356 patients with genotype 3 chronic HCV undergoing treatment with peg-interferon and ribavirin and was compared with matched controls. IL28b genotyping followed by DNA sequencing was performed to identify the CC, CT, or TT genotypes. Two log reduction of HCV RNA at Day 7 (Quick Viral Response, QVR) and HCV RNA negativity at Day 28 (Rapid Viral Response, RVR) were analyzed with CC and non-CC genotypes in addition to other predictors of response. The associations of alleles with the response patterns were predicted. Sustained viral response was seen in 250 (70.2%) patients and the IL28b genotype CC/CT/TT distribution was 61.1%; 30.5%; and 8.4%, respectively. The non-CC genotypes were significantly higher in non-responders when compared to responders (67.6% vs. 38.9%, P < 0.001). Interestingly, the rapid viral response in responders was observed in 72.7% with the CC genotype and in 27.2% with the non-CC genotype (P < 0.001). Multivariate analysis showed CC genotype as an independent factor predicting the sustained viral response in patients infected with HCV genotype 3. In conclusion, the IL28b CT/TT genotype strongly correlates with treatment non-response in patients infected with HCV genotype 3 and CC genotype of IL28b is associated with higher quick viral response.Keywords
Funding Information
- Department of Biotechnology (DBT), Government of India
This publication has 34 references indexed in Scilit:
- Role of Interleukin-28B Polymorphism as a Predictor of Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Triple Therapy: A Systematic Review and Meta-AnalysisClinical Drug Investigation, 2013
- Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4European Journal of Clinical Microbiology & Infectious Diseases, 2013
- Role of IL‐28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg‐Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varicesJournal of Viral Hepatitis, 2012
- IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4Journal of Viral Hepatitis, 2012
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- Cutting Edge: Programmed Death-1 Expression Is Increased on Immunocytes in Chronic Hepatitis C Virus and Predicts Failure of Response to Antiviral Therapy: Race-Dependent DifferencesThe Journal of Immunology, 2008
- Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearanceGut, 2006
- Mechanism of action of interferon and ribavirin in treatment of hepatitis CNature, 2005
- Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patientsJournal of Hepatology, 1998
- Treatment of Chronic Hepatitis C With Interferon With or Without Ursodeoxycholic AcidJournal of Clinical Gastroenterology, 1998